...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >HER2|[sol]|neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
【24h】

HER2|[sol]|neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder

机译：HER2 | [sol] | neu在膀胱肌浸润性移行细胞癌发展中的过度表达

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The mortality from transitional cell carcinoma (TCC) of the urinary bladder increases significantly with the progression of superficial or locally invasive disease (pTa/pT1) to detrusor muscle-invasive disease (pT2+). The most common prognostic markers in clinical use are tumour stage and grade, which are subject to considerable intra- and interobserver variation. Polysomy 17 and HER2eu gene amplification and protein overexpression have been associated with more advanced disease. Standardised techniques of fluorescence in situ hybridisation and immunohistochemistry, which are currently applied to other cancers with a view to offering anti-HER2eu therapies, were applied to tumour pairs comprising pre- and postinvasive disease from 25 patients undergoing treatment for bladder cancer. In the preinvasive tumours, increased HER2eu copy number was observed in 76% of cases and increased chromosome 17 copy number in 88% of cases, and in the postinvasive group these values were 92 and 96%, respectively (not significantly different P=0.09 and 0.07, respectively). HER2 gene amplification rates were 8% in both groups. Protein overexpression rates were 76 and 52%, respectively, in the pre- and postinvasive groups (P=0.06). These results suggest that HER2eu abnormalities occur prior to and persist with the onset of muscle-invasive disease. Gene amplification is uncommon and other molecular mechanisms must account for the high rates of protein overexpression. Anti-HER2eu therapy might be of use in the treatment of TCC.
机译：随着浅表或局部浸润性疾病（pTa / pT1）向逼尿肌浸润性疾病（pT2 +）的发展，膀胱移行细胞癌（TCC）的死亡率显着增加。临床上最常见的预后标志物是肿瘤的阶段和等级，观察者之间和观察者之间会有很大差异。多态性17和HER2 / neu基因扩增和蛋白质过表达与更晚期的疾病有关。荧光原位杂交和免疫组织化学的标准化技术，目前已应用于其他癌症，以提供抗HER2 / neu疗法，已应用于包括25例接受膀胱癌治疗的浸润前后疾病的肿瘤对。在浸润前肿瘤中，观察到HER2 / neu拷贝数增加的发生率为76％，而在17染色体上的染色体数目则增加了88％，而在浸润后组中，这些值分别为92％和96％（不显着） P分别为0.09和0.07）。两组的HER2基因扩增率均为8％。在浸润前和浸润后组中，蛋白质过表达率分别为76％和52％（P = 0.06）。这些结果表明，HER2 / neu异常发生在肌肉浸润性疾病发作之前并持续。基因扩增并不常见，其他分子机制也必须解释蛋白质过度表达的高比率。抗HER2 / neu疗法可能在TCC的治疗中有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号